NDA 206256 · Acrotech Biopharma
Beleodaq
Belinostat · Intravenous · Histone Deacetylase Inhibitor
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jul 3, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
2 Phase 3, 4 recruiting
FAERS reports
358
318 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2025.
Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.( 1 )
Mechanism: Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro , belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 3, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelSummary ReviewReview
1 products under this application
- BELEODAQ · BELINOSTAT 500MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Belinostat" as an intervention, any sponsor and status, largest first.
- To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLPivotal-lookingActive, not recruiting
Acrotech Biopharma Inc.Industry
NCT06072131 · 504 participants (planned) · Start Oct 4, 2023 · Primary completion Jul 2030
Drug: Belinostat Injection; Pralatrexate Injection and 2 more · For: Peripheral T Cell Lymphoma
Sites: Clovis, California; Santa Monica, California; Aurora, Colorado · 58 sites in all
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPivotal-lookingRecruiting
Corvus Pharmaceuticals, Inc.Industry
NCT06561048 · 150 participants (planned) · Start Oct 2, 2024 · Primary completion Nov 2027
Drug: Soquelitinib; Belinostat and 1 more · For: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma and 4 more
Sites: Duarte, California; Irvine, California; San Francisco, California · 37 sites in all
Spectrum Pharmaceuticals, IncIndustry
NCT00865969 · 129 participants · Start Dec 15, 2008 · Primary completion Nov 5, 2013
Drug: Belinostat · For: Peripheral T-cell Lymphoma
Sites: Duarte, California; La Verne, California; Palm Springs, California · 117 sites in all
Valerio TherapeuticsIndustry
NCT00413075 · 121 participants · Start Jun 2006 · Primary completion Aug 2011
Drug: oral belinostat · For: Solid Tumor; Lymphoma
Sites: New Haven, Connecticut; New York, New York; Houston, Texas · 6 sites in all
Valerio TherapeuticsIndustry
NCT00873119 · 89 participants · Start Feb 2009 · Primary completion Dec 2012
Drug: belinostat, carboplatin, paclitaxel; carboplatin, paclitaxel · For: Carcinoma of Unknown Primary
Sites: Fort Myers, Florida; Marietta, Georgia; Baton Rouge, Louisiana · 23 sites in all
Valerio TherapeuticsIndustry
NCT00421889 · 80 participants · Start Aug 2005 · Primary completion Feb 2009
Drug: belinostat; Paclitaxel and 1 more · For: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer and 1 more
Sites: Newport Beach, California; Orlando, Florida; Covington, Louisiana · 11 sites in all
- Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic DysfunctionCompleted
National Cancer Institute (NCI)NIH
NCT01273155 · 72 participants · Start Jan 10, 2011 · Primary completion Oct 25, 2017
Drug: Belinostat · For: Neoplasms; Lymphomas
Sites: Davis, California; Duarte, California; Los Angeles, California · 7 sites in all
National Cancer Institute (NCI)NIH
NCT06406465 · 60 participants (planned) · Start Nov 24, 2026 · Primary completion Jul 30, 2027
Drug: Belinostat; Cisplatin and 1 more · For: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine and 2 more
Sites: Bethesda, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression77
- nausea59
- anaemia49
- death43
- vomiting43
- dyspnoea36
- platelet count decreased33
- fatigue32
- constipation28
- neutropenia26
- diarrhoea25
- white blood cell count decreased24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 12 |
| 2020 | 14 |
| 2021 | 70 |
| 2022 | 49 |
| 2023 | 57 |
| 2024 | 40 |
| 2025 | 48 |
| 2026 | 25 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Beleodaq (Belinostat) · HCPCS J9032
2024 spending
$13.5M
Beneficiaries
74
1,352 claims
Per beneficiary
$181,893
2024 ASP limit $49.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,653,903 |
| 2021 | $5,459,426 |
| 2022 | $9,011,480 |
| 2023 | $10,513,040 |
| 2024 | $13,460,107 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA, Horwitz S, Masszi T, et al. · J Clin Oncol 2015 · Clinical Trial, Phase II, Multicenter Study
- BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, et al. · Blood 2021 · Clinical Trial, Multicenter Study
- Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Shafer D, Kagan AB, Rudek MA, et al. · Cancer Chemother Pharmacol 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.
Gurbani SS, Yoon Y, Weinberg BD, et al. · Tomography 2019 · Controlled Clinical Trial, Research Support, N.I.H., Extramural
- Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
Goey AK, Sissung TM, Peer CJ, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Research Support, N.I.H., Intramural
- UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Peer CJ, Goey AK, Sissung TM, et al. · J Clin Pharmacol 2016 · Clinical Trial, Research Support, N.I.H., Intramural
Sponsor: Acrotech Biopharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.